Montpellier, France, January 19, 2016 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, has announced the appointment of Teresa Prego to the position of Director of Marketing.
Based at Medtech's U.S. branch, Ms. Prego will develop and implement the Company's marketing policy, with a strong focus on supporting commercial operations in the U.S.. This includes the marketing strategy and commercial launch of the ROSA™ Spine robot in the U.S., which recently received 510K clearance from the U.S. Food and Drug Administration (FDA).
Ms. Prego has had more than 20 years of experience in strategic marketing within the medical field. Prior to Medtech, she served as a Senior Consultant at Andersen Consulting (now Accenture), held roles with Bayer, Boston Scientific, Aspect Medical and, most recently, was the Marketing Director at Tenet Healthcare.
“Teresa Prego's marketing experience and expertise in the U.S. medical sector are major assets for Medtech,” said Bertin Nahum, CEO and Founder of Medtech. “Her appointment will contribute to driving adoption of our technology in various markets, including the launch of ROSA Spine in the U.S. True to the commitments we made at the time of the IPO, we are successfully executing on our growth strategy with additions to the management team to keep pace with the expansion of our commercial activity.”
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40
Tel : +33 (0)1 53 67 36 77
Alexandra Prisa (EU)
Tel. : +33(0)1 53 67 36 90
Joanna Zimmerman (US)
Tel : +1 646-536-7006
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|MEDTECH||Euronext Paris||50.00 (c)||0.00%||0|